PEG-coated and Gd-loaded fluorescent silica nanoparticles for targeted prostate cancer magnetic resonance imaging and fluorescence imaging

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Kumar V, Bora GS, Kumar R, Jagannathan NR. Multiparametric (mp) MRI of prostate cancer. Prog Nucl Magn Reson Spectrosc. 2018;105:23–40. doi:10.1016/j.pnmrs.2018.01.00129548365
   PubMedGoogle Scholar
• Dou S, Bai Y, Shandil A, et al. Detecting prostate cancer and prostatic calcifications using advanced magnetic resonance imaging. Asian J Androl. 2017;19(4):439–443. doi:10.4103/1008-682X.17784027004542
   PubMedGoogle Scholar
• Quon JS, Moosavi B, Khanna M, Flood TA, Lim CS, Schieda N. False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance. Insights Imaging. 2015;6(4):449–463. doi:10.1007/s13244-015-0411-3
   PubMedGoogle Scholar
• Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697–1705. doi:10.2967/jnumed.115.16129926294298
   PubMed Web of Science ®Google Scholar
• Xing H, Bu W, Zhang S, et al. Multifunctional nanoprobes for upconversion fluorescence, MR and CT trimodal imaging. Biomaterials. 2012;33(4):1079–1089. doi:10.1016/j.biomaterials.2011.10.03922061493
   PubMed Web of Science ®Google Scholar
• Harrison VS, Carney CE, MacRenaris KW, Waters EA, Meade TJ. Multimeric near IR-MR contrast agent for multimodal in vivo imaging. J Am Chem Soc. 2015;137(28):9108–9116. doi:10.1021/jacs.5b0450926083313
   PubMedGoogle Scholar
• Wang J, Shah ZH, Zhang S, Lu R. Silica-based nanocomposites via reverse microemulsions: classifications, preparations, and applications. Nanoscale. 2014;6(9):4418–4437. doi:10.1039/c3nr06025j24562100
   PubMed Web of Science ®Google Scholar
• Stöber W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in the micron size range. J Colloid Interface Sci. 1968;26(1):62–69. doi:10.1016/0021-9797(68)90272-5
   Web of Science ®Google Scholar
• Chen F, Hableel G, Zhao ER, Jokerst JV. Multifunctional nanomedicine with silica: role of silica in nanoparticles for theranostic, imaging, and drug monitoring. J Colloid Interface Sci. 2018;521:261–279. doi:10.1016/j.jcis.2018.02.05329510868
   PubMed Web of Science ®Google Scholar
• González-Alvarez M, Coll C, Gonzalez-Alvarez I, et al. Gated mesoporous silica nanocarriers for a “two-step” targeted system to colonic tissue. Mol Pharm. 2017;14(12):4442–4453. doi:10.1021/acs.molpharmaceut.7b0056529064714
   PubMed Web of Science ®Google Scholar
• Chen C, Feng N, Guo Q, et al. Template-directed fabrication of MIL-101(Cr)/mesoporous silica composite: layer-packed structure and enhanced performance for CO2 capture. J Colloid Interface Sci. 2018;513:891–902. doi:10.1016/j.jcis.2017.12.01429232648
   PubMedGoogle Scholar
• Gounani Z, Asadollahi MA, Pedersen JN, et al. Mesoporous silica nanoparticles carrying multiple antibiotics provide enhanced synergistic effect and improved biocompatibility. Colloids Surf B Biointerfaces. 2019;175:498–508. doi:10.1016/j.colsurfb.2018.12.03530572158
   PubMed Web of Science ®Google Scholar
• Gonçalves MC. Sol-gel silica nanoparticles in medicine: a natural choice. Design, synthesis and products. Molecules. 2018;23(8):2021. doi:10.3390/molecules23082021
   PubMed Web of Science ®Google Scholar
• Jiang W, He X, Fang H, Zhou X, Ran H, Guo D. Novel gadopentetic acid-doped silica nanoparticles conjugated with YPSMA-1 targeting prostate cancer for MR imaging: an in vitro study. Biochem Biophys Res Commun. 2018;499(2):202–208. doi:10.1016/j.bbrc.2018.03.12429555471
   PubMedGoogle Scholar
• Nooney R, O’Connell C, Roy S, et al. Synthesis and characterisation of far-red fluorescent cyanine dye doped silica nanoparticles using a modified microemulsion method for application in bioassays. Sensor Actuat B Chem. 2015;221:470–479. doi:10.1016/j.snb.2015.06.117
   Web of Science ®Google Scholar
• O’Connell CL, Nooney R, McDonagh C. Cyanine5-doped silica nanoparticles as ultra-bright immunospecific labels for model circulating tumour cells in flow cytometry and microscopy. Biosens Bioelectron. 2017;91:190–198. doi:10.1016/j.bios.2016.12.02328006688
   PubMed Web of Science ®Google Scholar
• Lake ST, Greene KL, Westphalen AC, et al. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017;7(1):77. doi:10.1186/s13550-017-0327-728929350
   PubMedGoogle Scholar
• Kiess AP, Banerjee SR, Mease RC, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59(3):241–268.26213140
   PubMed Web of Science ®Google Scholar
• Tsourlakis MC, Klein F, Kluth M, et al. PSMA expression is highly homogenous in primary prostate cancer. Appl Immunohistochem Mol Morphol. 2015;23(6):449–455. doi:10.1097/PAI.000000000000011026153794
   PubMedGoogle Scholar
• Nandiyanto ABD, Kim SG, Iskandar F, Okuyama K. Synthesis of spherical mesoporous silica nanoparticles with nanometer-size controllable pores and outer diameters. Micropor Mesopor Mat. 2009;120(3):447–453. doi:10.1016/j.micromeso.2008.12.019
   Web of Science ®Google Scholar
• Tan J, Yang N, Zhong L, et al. A new theranostic system based on endoglin aptamer conjugated fluorescent silica nanoparticles. Theranostics. 2017;7(19):4862–4876. doi:10.7150/thno.1910129187909
   PubMed Web of Science ®Google Scholar
• Koopaei MN, Dinarvand R, Amini M, et al. Docetaxel immunonanocarriers as targeted delivery systems for her 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomed. 2011;6:1903–1912.
   PubMed Web of Science ®Google Scholar
• Lee S, George Thomas R, Ju Moon M, et al. Near-infrared heptamethine cyanine based iron oxide nanoparticles for tumor targeted multimodal imaging and photothermal therapy. Sci Rep. 2017;7(1):2108. doi:10.1038/s41598-017-01108-528522841
   PubMedGoogle Scholar
• Cao M, Wang P, Kou Y, et al. Gadolinium (III)-chelated silica nanospheres integrating chemotherapy and photothermal therapy for cancer treatment and magnetic resonance imaging. ACS Appl Mater Interfaces. 2015;7(45):25014–25023. doi:10.1021/acsami.5b0693826418578
   PubMedGoogle Scholar
• Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43(12):817–828. doi:10.1097/RLI.0b013e318185217119002053
   PubMed Web of Science ®Google Scholar
• Xu W, Lu Y. A smart magnetic resonance imaging contrast agent responsive to adenosine based on a DNA aptamer-conjugated gadolinium complex. Chem Commun. 2011;47(17):4998–5000. doi:10.1039/c1cc10161g
   PubMed Web of Science ®Google Scholar
• Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, et al. A novel 111In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT/CT imaging of prostate cancer. J Nucl Med. 2015;56(7):1094–1099. doi:10.2967/jnumed.115.15672925977460
   PubMed Web of Science ®Google Scholar
• Tykvart J, Navrátil V, Sedlák F, et al. Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA). Prostate. 2014;74(16):1674–1690. doi:10.1002/pros.2288725262926
   PubMedGoogle Scholar
• Zhao L, Ge X, Yan G, et al. Double-mesoporous core-shell nanosystems based on platinum nanoparticles functionalized with lanthanide complexes for in vivo magnetic resonance imaging and photothermal therapy. Nanoscale. 2017;9(41):16012–16023. doi:10.1039/c7nr04983h29022987
   PubMedGoogle Scholar
• Homayoon B, Diwakar H, Strovski E, et al. Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison. Abdom Imaging. 2014;39(5):955–962. doi:10.1007/s00261-014-0123-z24676875
   PubMedGoogle Scholar